Product Images Atorvastatin Calcium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 5 images provide visual information about the product associated with Atorvastatin Calcium NDC 68071-4472 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
PDP - 68071 4472 09 t70
This is a label for a medicine bottle of Atorvastatin Calcium 80mg tablets. The label includes important information such as keeping the medicine out of reach of children, the expiration date, and the lot number. It also advises to store the product at a controlled temperature of 63-77 °F. It is for prescription use only and the manufacturer's label should be consulted for a full list of ingredients. There are four instances of the same NDC code, lot number, and Rx number.*
Chemical Structure - atorvastatin calcium tabs form i a205300 1
figure 1 - atorvastatin calcium tabs form i a205300 2
The text describes the cumulative incidence (%) of Atorvastatin and Placebo over a 3.5-year period. The table shows that Atorvastatin has a lower incidence rate (3.0%) compared to Placebo (1.0%). The results are statistically significant with a p-value of 0.0005. There are also numbers on the X-axis indicating scale measurements.*
Figure 2 - atorvastatin calcium tabs form i a205300 3
This is a graph showing Cumulative Hazard (%) and Time to First Primary Endpoint Through Four (4) Years of Follow-up (Years) . The graph also includes an HR of 0.63 (with a 95% confidence interval of 0.48 to 0.83) and a p-value of 0.001. No further information is available to provide more context.*
figure 3 - atorvastatin calcium tabs form i a205300 4
The text describes a study which lists percentages of subjects who experienced an event after taking different doses of Atorvastatin. The effectiveness of the treatment is shown by a hazard ratio of 0.78 indicating a statistically significant reduction in the occurrence of cardiovascular events. The study also displays a graph demonstrating the time it took for subjects to experience the first major cardiovascular endpoint while taking Atorvastatin.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
